Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Vyant Bio, Inc. (VYNT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.2600-0.0400 (-3.08%)
At close: 03:59PM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at Neuroscience 2022 Hosted by the Society for Neuroscience

    “Targeting specific functional rescue in a Rett patient cortical organoid disease model” CHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine lear

  • GlobeNewswire

    Vyant Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

    CHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that the Company has received formal notice from The Nas

  • GlobeNewswire

    Vyant Bio Reports Third Quarter 2022 Results and Provides Strategic and Business Highlights

    Q3 2022 and Recent Scientific and Business Highlights Completed the sale of its vivoPharm subsidiary to Reaction Biology Corporation for $5.5 million in an upfront cash paymentDelivered platform and poster presentations at the 2022 CDKL5 Forum hosted by the Loulou FoundationEntered into a master services agreement and related statement of work with an Australian CRO in November 2022 to support the Company’s adult Rett Syndrome clinical trialProgress with licensing our iPSC technology to transiti

Advertisement
Advertisement